Zuhrie S R, Harris R, Freeman C B, MacIver J E, Geary C G, Delamore I W, Tooth J A
Br J Cancer. 1980 Mar;41(3):372-7. doi: 10.1038/bjc.1980.60.
Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intradermal BCG plus allogeneic cells or to "no maintenance". Patients receiving immunotherapy had significantly longer remission (P = 0.039) and survival from remission (P = 0.044) as assessed by the log-rank test. The median duration of first remission for 21 patients receiving immunotherapy was 35.14 weeks, compared with 19.71 weeks for 20 patients on no maintenance, and the median survival from remission was doubled in patients receiving immunotherapy. The value of adequate consolidation chemotherapy is confirmed by the comparatively long first remissions in both groups compared with our previous trials, whilst avoidance of maintenance chemotherapy possibly allowed frequent second remissions and similar post-relapse survival in patients from both treatment arms.
41例成年急性髓性白血病患者接受柔红霉素和阿糖胞苷诱导缓解治疗，随后接受环磷酰胺加6-硫鸟嘌呤的6周巩固治疗。然后将他们随机分为接受皮内卡介苗加同种异体细胞的免疫治疗组或“不进行维持治疗”组。通过对数秩检验评估，接受免疫治疗的患者缓解期显著延长（P = 0.039），缓解后的生存期也显著延长（P = 0.044）。接受免疫治疗的21例患者首次缓解的中位持续时间为35.14周，而20例不进行维持治疗的患者为19.71周，接受免疫治疗的患者缓解后的中位生存期翻倍。与我们之前的试验相比，两组相对较长的首次缓解期证实了充分巩固化疗的价值，而避免维持化疗可能使两组患者都能频繁获得第二次缓解并在复发后有相似的生存期。
